Advertisement
Screener

ARS Pharmaceuticals, Inc. (SPRY) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

ARS Pharmaceuticals, Inc. Total Long-Term Debt

ARS Pharmaceuticals, Inc. (SPRY) had Total Long-Term Debt of $96.68 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Liabilities

us-gaap:LongTermDebt · last filed 2026-08-13

  • 2026-06-30: Long-term Debt $96.68M.
  • 2026-03-31: Long-term Debt $96.52M.
  • 2025-12-31: Long-term Debt $96.37M.
  • 2025-09-30: Long-term Debt $96.23M.
Period endLong-term Debt
2026-06-30$96.68M
10-Q · filed 2026-08-13
2026-03-31$96.52M
10-Q · filed 2026-05-15
2025-12-31$96.37M
10-Q · filed 2026-08-13
2025-09-30$96.23M
10-Q · filed 2025-11-10
2024-12-31$0.00
10-K · filed 2026-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85